Walter M. Stadler, MD
Following the wave of FDA approvals in prostate cancer, Walter M. Stadler, MD, explained that the field has undergone a dramatic transformation, but research should be focused on immunotherapy, sequencing strategies, and biomarkers.
It has been theorized that PARP inhibitors provide synergistic effects in combination with immunotherapy, and a cohort of the ongoing phase I KEYNOTE-365 trial is examining the combination of pembrolizumab (Keytruda) and olaparib (Lynparza; NCT02861573) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Moreover, a randomized phase II trial is investigating the combination of abiraterone acetate (Zytiga) and prednisone with or without olaparib versus single-agent olaparib in the same population (NCT03012321).
... to read the full story